
AVR Stock Forecast & Price Target
AVR Analyst Ratings
Bulls say
Anteris Technologies Glb is viewed positively because DurAVR’s single-piece, biomimetic design is positioned as a structural leap over existing TAVR valves, with physician-led feedback, head-to-head PARADIGM testing, and early hemodynamic data suggesting native-valve-like flow and lower gradients than competitors. The company also has unusually strong clinical and strategic validation, including 130+ EFS/EMBARK patients, ~200 patients treated to date, a 55,000+ patient history behind ADAPT tissue, and Medtronic’s $90M investment, all of which support the view that the platform is being de-risked while demand remains high. Financially, it ended 2Q26 with $260.9M in cash, R&D rose 34% Q/Q to $23.4M as manufacturing and trial infrastructure scaled, and full French clearance expands PARADIGM into one of Europe’s largest TAVR markets, reinforcing runway and growth optionality.
Bears say
Anteris Technologies Glb is facing a highly uncertain fundamental backdrop because its valuation depends heavily on PARADIGM trial outcomes and eventual FDA commercial approval, both of which could disappoint relative to management and analyst expectations or take longer than the company can comfortably fund. The company has already incurred significant operating losses and negative cash flow to support development, raising the risk that expenses continue to outpace resources and push it toward inoperability if capital needs increase. In addition, DurAVR still lacks a proven marketing or sales strategy, which could slow adoption by the medical community and leave the business without a clear path to meaningful commercialization.
This aggregate rating is based on analysts' research of Anteris Technologies Global Corp and is not a guaranteed prediction by Public.com or investment advice.
AVR Analyst Forecast & Price Prediction
Start investing in AVR
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Anteris Technologies Global Corp (AVR) Forecast
AVR Analyst Forecast & Price Prediction
Start investing in AVR
Order type
Buy in
Order amount
Est. shares
0 shares